Related Experiment Videos
Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study
V Smith1, J T Van Praet, B Vandooren
1Department of Rheumatology, Ghent University Hospital 0K12-IB, De Pintelaan 185, B-9000, Gent, Belgium. Vanessa.Smith@ugent.be
Annals of the Rheumatic Diseases
|December 24, 2008
Summary
Rituximab shows promise for diffuse cutaneous systemic sclerosis (dc-SSc) skin disease. This study found rituximab well-tolerated, effectively depleting B-cells and improving skin sclerosis scores.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Diffuse cutaneous systemic sclerosis (dc-SSc) is a severe autoimmune condition characterized by skin thickening and potential organ damage.
- Current treatments for dc-SSc have limitations, necessitating exploration of novel therapeutic approaches.
Purpose of the Study:
- To evaluate the safety and efficacy of rituximab in patients with diffuse cutaneous systemic sclerosis (dc-SSc).
Main Methods:
- An open-label study involving eight dc-SSc patients treated with rituximab infusions at baseline and day 15.
- Assessments included B-cell counts (CD19+), skin sclerosis scores, organ function indices, disability, and skin histopathology.
Main Results:
- Rituximab effectively depleted peripheral B-cells in all patients.
- Significant improvements were observed in skin sclerosis scores, dermal collagen content, and myofibroblast numbers.
- Two serious adverse events were reported, deemed unrelated to rituximab.
Conclusions:
- Rituximab appears to be a safe and potentially effective treatment for the skin manifestations of dc-SSc.
